[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581897":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":39,"collaborators":11,"id":41,"slug":11,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":11,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":11,"studyType":53,"phases":54,"briefSummary":57,"conditions":58,"keywords":11,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Zhejiang Provincial People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.","EXPERIMENTAL",null,[13],"Drug: NKG2D CAR-NK with PD-1 Antibody",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","NKG2D CAR-NK with PD-1 Antibody","Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Minghua Ge","CONTACT","+86-0571 87666666","geminghua@hmc.edu.cn",[27],{"facility":5,"status":11,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":11},"Hangzhou","Zhejiang","310014","China","CN",{"type":34,"coordinates":35},"Point",[36,37],120.16142,30.29365,{"lat":37,"lon":36},{"type":40,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100581897",false,"NCT06856278","Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC","Clinical Exploratory Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of Anaplastic Thyroid Cancer (ATC)","Inclusion Criteria:\n\n1. Age 18-75 years (including boundary values), male or female.\n2. Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm.\n3. Liver and kidney function is good, and can tolerate treatment.\n4. Be able to cooperate with the completion of treatment and follow-up work.\n5. No other systemic diseases, including other malignancies.\n\nExclusion Criteria:\n\n1. Need to breastfeed the baby or have fertility needs；\n2. Immune system diseases;\n3. Diseases of the blood system;\n4. Mental system diseases;\n5. Interstitial pneumonia, lung disease, etc.;\n6. Failure to follow rules of this study.","ALL","18 Years","75 Years",{"count":51,"type":52},30,"ESTIMATED","INTERVENTIONAL",[55,56],"PHASE1","PHASE2","The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.",[59],"Anaplastic Throid Carcinoma","NOT_YET_RECRUITING","2025-02-26",{"date":63,"type":64},"2025-03-04","ACTUAL",{"date":66,"type":52},"2025-02-22",{"date":68,"type":52},"2029-03-01",{"name":5,"class":6},1]